The Celltrion(068270) biosimilar portfolio is steadily increasing its market share in Europe.
According to IQVIA on the 10th, OMLYCLO, an Omalizumab biosimilar launched in Europe in Sep. last year, recorded about a 16% market share in Europe as of the first quarter of this year.
In particular, it topped the Omalizumab market in Spain six months after launch with a 71% share. Prescriptions also expanded quickly in Portugal (47%), Ireland (41%) and Norway (31%).
The oncology biosimilar Vegzelma also recorded about a 28% market share in Europe over the same period, maintaining the No. 1 position in the bevacizumab biosimilar market for 1 year and 9 months in a row.
Autoimmune disease treatments also continued to grow. Yuflyma, an adalimumab biosimilar, ranked No. 1 in prescriptions for a year in a row with about a 22% market share in Europe. In particular, it showed high shares in the United Kingdom (49%) and Italy (46%).
Steqeyma, a ustekinumab biosimilar, recorded about a 9% market share in Europe. Prescriptions are increasing mainly in Portugal (41%), Sweden (28%) and Italy (20%).
Celltrion expects sales of follow-up products to expand further, considering market characteristics such as concentrated tenders in major European countries in the second half, overlap with initial supply volumes, and year-end inventory buildup demand. The company plans to expand local sales staff and strengthen marketing activities at major conferences such as the European Respiratory Society (ERS) and the United European Gastroenterology Week (UEGW).